| Evidence of β-blockers drug repurposing for the treatment of triple negative breast cancer: A systematic review A Spini, G Roberto, R Gini, C Bartolini, L Bazzani, S Donnini, S Crispino, ... Neoplasma 66 (6), 963-970, 2019 | 21 | 2019 |
| Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity A Spini, V Giudice, V Brancaleone, MG Morgese, S De Francia, ... Pharmacological Research 173, 105848, 2021 | 19 | 2021 |
| Repurposing of drugs for triple negative breast cancer: An overview A Spini, S Donnini, P Pantziarka, S Crispino, M Ziche ecancermedicalscience 14, 2020 | 18 | 2020 |
| A Systematic Review of Case-Identification Algorithms for 18 Conditions Based on Italian Healthcare Administrative Databases: A Study Protocol. C Canova, L Simonato, I Baldi, T Dalla Zuanna, D Gregori, S Danieli, ... Epidemiologia e Prevenzione 43 (4 Suppl 2), 8-16, 2019 | 14 | 2019 |
| First-line pharmacotherapies and survival among patients diagnosed with non-resectable NSCLC: a real-life setting study with gender prospective A Spini, R Gini, P Rosellini, A Singier, C Bellan, A Pascucci, L Leoncini, ... Cancers 13 (23), 6129, 2021 | 12 | 2021 |
| Risk of intraocular pressure increase with intravitreal injections of Vascular Endothelial Growth Factor Inhibitors: A cohort study A Spini, S Giometto, S Donnini, M Posarelli, F Dotta, M Ziche, GM Tosi, ... American journal of ophthalmology 248, 45-50, 2023 | 10 | 2023 |
| A Systematic Review of Case-Identification Algorithms Based on Italian Healthcare Administrative Databases for Three Relevant Diseases of the Cardiovascular System: Acute … G Hyeraci, A Spini, G Roberto, R Gini, C Bartolini, E Lucenteforte, ... Epidemiologia e prevenzione 43 (4 Suppl 2), 37-50, 2019 | 10 | 2019 |
| Safety of anti-angiogenic drugs in pediatric patients with solid tumors: A systematic review and meta-analysis A Spini, V Ciccone, P Rosellini, M Ziche, E Lucenteforte, F Salvo, ... Cancers 14 (21), 5315, 2022 | 9 | 2022 |
| Scoping review on platelets and tumor angiogenesis: do we need more evidence or better analysis? A Filippelli, C Del Gaudio, V Simonis, V Ciccone, A Spini, S Donnini International Journal of Molecular Sciences 23 (21), 13401, 2022 | 6 | 2022 |
| Real word evidence on rituximab utilization: Combining administrative and hospital-pharmacy data G Roberto, A Spini, C Bartolini, V Moscatelli, A Barchielli, D Paoletti, ... Plos one 15 (3), e0229973, 2020 | 6 | 2020 |
| Antiangiogenic drugs: Chemosensitizers for combination cancer therapy S Donnini, A Filippelli, V Ciccone, A Spini, E Ristori, M Ziche, L Morbidelli Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy, 29-66, 2022 | 4 | 2022 |
| Sex differences in the utilization of drugs for COVID‐19 treatment among elderly residents in a sample of Italian nursing homes A Spini, G Crescioli, S Donnini, M Ziche, F Collini, F Gemmi, G Virgili, ... Pharmacoepidemiology and Drug Safety 31 (5), 489-494, 2022 | 2 | 2022 |
| Real-World Utilization of Target-and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data A Spini, G Hyeraci, C Bartolini, S Donnini, P Rosellini, R Gini, M Ziche, ... International Journal of Environmental Research and Public Health 18 (14), 7679, 2021 | 2 | 2021 |
| Validity of Italian administrative healthcare data in describing the real-world utilization of infusive antineoplastic drugs: the study case of rituximab use in patients … C Bartolini, G Roberto, A Girardi, V Moscatelli, A Spini, A Barchielli, ... Frontiers in Oncology 13, 1059109, 2023 | 1 | 2023 |
| Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry A Spini, P Rosellini, C Bellan, F Furiesi, S Giorgi, S Donnini, R Gini, ... Plos one 17 (6), e0269232, 2022 | 1 | 2022 |
| Utilization of drugs reimbursed by the Italian healthcare service for the treatment of COVID19 during the first pandemic wave: Gender differences in the general and nursing … G Roberto, N Lombardi, G Crescioli, F Collini, F Gemmi, A Vannacci, ... Pharmacoepidemiology and Drug Safety, 391-392, 2021 | 1 | 2021 |
| Pattern of use of intravitreal drugs with antiangiogenic properties for age-related macular degeneration and other vascular retinopathies R Gini, G Roberto, G Virgili, F Attanasio, A Spini, V Moscatelli, C Bartolini, ... PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 26, 583-583, 2017 | 1 | 2017 |
| Uncovering Knowledge Gaps in the Safety Profile of Antiangiogenic Drugs in Cancer Patients: Insights from Spontaneous Reporting Systems Studies V Ciccone, M Ziche, A Spini, S Donnini Pharmaceuticals 16 (6), 867, 2023 | | 2023 |
| Signals of adverse reactions to anti-angiogenic drugs in cancer: a scoping review of the literature from studies of spontaneous reporting systems V Ciccone, M Ziche, A Spini, S Donnini Authorea Preprints, 2023 | | 2023 |
| Oral Presentation: Risk of Glaucoma Diagnosis in Patients Who Received Intravitreal Injections of VEGF Inhibitors: A Cohort Study A Spinj, S Giometto, S Donnini, M Posarelli, F Dotta, G Tosi, A Girardi, ... Drug Safety 45 (10), 1121-1122, 2022 | | 2022 |
